Prognostic factors in renal cell carcinoma;Factores pronósticos del carcinoma de células renales

Actas Urologicas Espanolas

Volumn 33, Issue 5, 2009, Pages 575-583

  Medina López, Rafael A ^a   Conde Sánchez, José M ^a   Congregado Ruiz, Carmen B ^a   Resina, Raquel González ^a   Navarro, Salvador Mármol ^a   Torrubia Romero, Francisco J ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Prognostic factors; Renal cell carcinoma; Survival rates

Indexed keywords

EID: 67650753184     PISSN: 02104806     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0210-4806(09)74192-0     Document Type: Article

References (68)

1. La situación del cáncer en España. Ministerio de Sanidad y Consumo. Madrid, 2005. ISBN: 84-7670-673-681.
2. Berrino F, De Angelis R, Sant M, Rosso S, Bielska-Lasota M, Coebergh JW et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-1999: results of the EUROCARE-4 study. Lancet Oncol 2007;8(9):773-783.
3. Kirkali Z, Tuzel E, Mungan MU. Recent advances in kidney cancer and metastatic disease. BJU Int. 2001;88(8):818-824.
4. López-Beltran A, Scarpelli M, Montironi R, Kirkali Z. 2004 WHO classification of the renal tumors of the adults. 2006;49(5):798-805. Epub 2006 Jan 17.
5. Ljungberg B. Prognostic markers in renal cell carcinoma. Curr Opin Urol. 2007;17(5):303-308.
6. Lane BR, Kattan MW. Predicting outcomes in renal cell carcinoma. Curr Opin Urol. 2005;15(5):289-297.
7. Belldegrun AS. Renal Cell Carcinoma: Prognostic Factors and Patient Selection. Eur Urol Supp. 2007;6:477-483.
8. AJCC. Cancer staging Manual, Sixth edition (2002). www.springer-ny.com/medicine.
9. Tsui KH, Shvarts O, Smith RB, et al. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using revised 1997 TNM staging criteria. J Urol 2000; 163(4):1090-1095.
10. Park WH, Eisen T. Prognostic factors in renal cell cancer. BJU Int 2007 May;99(5 Pt B):1277-1281.
11. Patard JJ, Shvarts O, Lam JS, Pantuck AJ, Kim HL, Ficarra V et al. Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. J Urol 2004;171(6 Pt 1):2181-2185.
12. Knight DA, Stadler WM. Prognostic factors in localized renal cell cancer. BJU Int 2007 May;99(5 Pt B):1212-1218.
13. Frank I, Blute ML, Leibovich BC, Cheville JC, Lohse CM, Zincke H. Independent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort. J Urol. 2005; 173(6):1889-1992.
14. Leibovich BC, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J Urol 2004;171(3):1066-1070.
15. Ficarra V, Guillè F, Schips L, de la Taille A, Prayer Galetti T, Tostain J et al. Proposal for revisión of the TNM classificarion system for renal cell carcinoma. Cancer 2005;104(10):2116-2123.
16. Ficarra V, Prayer-Galetti T, Novara G, Bratti E, Zanolla L, Dal Bianco M et al. Tumor-size breakpoint for prognostic stratification of localized renal cell carcinoma. Urol 2004;63(2):2365-2369; discussion 239-240.
17. Ortiz Gorraiz M, Vicente Prados FJ, Rosales Leal JL, Honrubia Vílchez B, Martínez Morcillo A, Cózar Olmo JM et al. Valoración de factores pronósticos de la supervivencia en una serie de 202 pacientes inervenidos por carcinoma de células renales. Actas Urol Esp 2005;29(2):179-189.
18. Budía Alba A, Gómez Pérez L, Bango V, Ruiz-Cerdá JI, Sempere A, Queipo JA, et al. Análisis de los factores pronósticos de progressión tumoral en el adenocarcinoma renal. Actas Urol Esp. 2007;31(8):831-844.
19. Medina López RA, Congregado Ruiz CB, Campoy Martínez P, Morales López A, Sánchez Gómez E, pascual del Pobil Moreno JL. Cáncer renal: análisis descriptivo de una serie de 267 casos intervenidos. Arch Esp Urol. 2001;54(5):423-428.
20. Giménez Bachs JM, Donate Moreno MJ, Salinas Sánchez AS, Pastor Navarro H, Carrión López P, Pastor Guzmán JM, et al. Supervivencia en relación a los factores pronósticos en una serie de pacientes con carcinoma de células renales. Arch Esp Urol. 2007;60(10):1167-1174.
21. Dall'Oglio MF, Ribeiro-Filho LA, Antunes AA, Crippa A, Nesrallah L, Gonçalves PD, et al. Microvascular tumor invasion, tumor size and Fuhrman grade: a pathological triad for profnostic evaluation of renal cell carcinoma. J Urol 2007;178 (2):525-428.
22. Klatte T, Chung J, Leppert JT, Lam JS, Pantuck AJ, Figlin RA, et al. Prognostic relevance of capsular involvement and collecting sytem invasion in stage I and II renal cell carcinoma. BJU Int. 2007;99(4): 821-824.
23. Han KR, Bui MH, Pantuck AJ, Freitas DG, Leibovich BC, Dorey FJ et al. TNM T3a renal cell carcinoma: adrenal gland involvement is not the same as renal fat invasion. J Urol. 2003;169(3):899-903.
24. Van Poppel H, Vandendriessche H, Boel K, Mertens V, Goethuys H, Haustermans K, et al. Microscopic vascular invasions ins the most relevat prognosticator after radical nephrectomy for clinicalli nonmetastatic renal cell carcinoma. J Urol. 1997;158(1):45-49.
25. Lang H, Lindner V, Letourneux H, Martin M, Saussine C, Jacqmin D, et al. Prognostic value of microscopic venous invasion in renal cell carcinoma: long-term follow-up. Eur Urol. 2004;46(3):331-335.
26. Ishimura T, Sakai I, Hara I, Eto H, Miyake H. Microscopic venous invasion in renal cell carcinoma as a predictor of recurrence after radical surgery. Int J Urol. 2004;11(5):264-268.
27. Madbouly K, Al-Qahtani SM, Ghazwani Y, Al-Shaibani S, Mansi MK. Microvascular tumor invasion: prognostic significance in low-stage renal cell carcinoma. Urology. 2007;69(4):670-674.
28. Kim HL, Zisman A, Han KR, Figlin RA, Belldegrun AS. Prognostic significance of venous thrombus in renal cell carcinoma. Are renal vein and inferior vena cava involvement different?. J Urol. 2004;171(2 Pt 1):588-591.
29. Moinzadeh A, Libertino JA. Prognostic significance of tumor thrombus level in patients with renal cell carcinoma and venous tumor thrombus extension. Is all T3b the same?. J Urol. 2004; 171(2 Pt 1):598-601.
30. Lambert EH, Pierorazio PM, Shabsigh A, Olsson CA, Benson MC, McKiernan JM. Prognostic risk stratification ans clinical outcomes in patients indergoing surgical treatment for renal cellc carcinoma with vascular tumor thrombus. Urology. 2007;69(6):1054-1058.
31. Boorjian SA, Sengupta S, Blute ML. Renal cell carcinoma: vena caval involvement. BJU Int. 2007; 99(5 Pt B):1239-1244.
32. Ficarra V, Galfano A, Verhoest G. Prognostic Factors and Staging Systems for Renal Cell Carcinoma. Eur Urology supp. 2007; 6: 623-629.
33. Pantuck AJ, Zisman A, Dorey F, Chao DH, Han KR, Said J, et al. Renal cell carcinoma with retroperitoneal limph nodes. Impact on survival an benefits of immunotherapy. Cancer. 2003;97(12):2995-3002.
34. Giberti C, Oneto F, Martorana G, Rovida S, Carmignani G. Radical nephrectomy for renal cell carcinoma: long-term results and prognostic factors on a series of 328 cases. Eur Urol. 1997;31(1):40-8.
35. Lam JS, Shvarts O, Leppert JT, Figlin RA, Belldegrun AS. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol. 2005;173(6):1853-1862.
36. Karakiewicz PI, Trinh QD, Bhojani N, Bensalah K, Salomon L, de la Taille A, et al. Renal Cell Carcinoma with Nodal Metastases in the Absence of Distant Metastatic Disease: Prognostic Indicators of Disease-Specific Survival. Eur Urol. 2007;51(6):1616-1624.
37. Lohse CM, Cheville JC. A review of prognostic pathologic features and algorithms for patients treated surgically for renal cell carcinoma. Clin Lab Med. 2005;25(2):433-464.
38. Congregado Ruiz B, Medina López RA, Sánchez Gómez E, Morales López A, Pascual del Pobil JL. Diagnóstico incidental del carcinoma renal. ¿implica un mejor pronóstico?. Actas Urol Esp. 2001;25(4):278-282.
39. Siemer S, Uder M, Humke U, Lindenmeier T, Moll V, Rüdenauer E, et al. Value of ultrasound in early diagnosis of renal cell carcinoma. Urologe A. 2000;39(2):149-153.
40. Lightfoot N, Conlon M, Kreiger N, Bissett R, Desai M, Warde P, et al. Impact of non-invasive imaging on increased incidental detection of renal cell carcinoma. Eur Urol. 2000;37(5):521-527.
41. Pantuck AJ, Zisman A, Belldegrum AS. The changinh natural history of renal cell carcinoma. J Urol. 2001;166(5):1611-1623.
42. Tsui KH, Shvarts O, Smith RB, Figlin R, de Kernion JB, Belldegrun A. Renal cell carcinoma: prognostic significance of incidentally detected tumors. J Urol. 2000;163(2):426-430.
43. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumos stage, size, grade and necrosis: the SSIGN score. J Urol. 2002;168(6):2395-2400.
44. Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P. A prospective prognistic nomogram for renal cell carcnoma. J Urol. 2001;166(1):63-67.
45. Zisman A, Pantuck AJ, Dorey F, Said JW, Shvarts O, Quintana D, et al. Improved prognostic of renal cell carcinoma using and integrated staging system. J Clin Oncol. 2001;19(6):1649-1657.
46. Zisman A, Pantuck AJ, Dorey F, Chao DH, Gitlitz BJ, Moldawer N, et al. Mathematical Model to Predict Individual Survival for Patients With Renal Cell Carcinoma. J Clin Oncol. 2002;20(5): 1368-1374.
47. O'Keefe SC, Marshall FF, Issa MM, Harmon MP, Petros JA. Thrombocytosis is associated with a significant increase in the cancer specific death rate after radical nephrectomy. J Urol. 2002;168(4 Pt 1):1378-1380.
48. Bensalah K, Leray E, Fergelot P, Rioux-Leclercq N, Tostain J, Guillé F,, et al. Prognostic value of thrombocytosis in renal cell carcinoma. J Urol. 2006;175(3 Pt 1):859-863.
49. Atzpodien J, Royston P, Wandert T, Reitz M; DGCIN - German Cooperative Renal Carcinoma Chemo-Immunotherapy Trials Group. Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer. 2003;88(3):348-353.
50. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982;6(7):655-663.
51. Novara G, Martignoni G, Artibani W, Ficarra V. Grading systems in renal cell carcinoma. J Urol. 2007;177(2):430-438.
52. Rioux-Leclercq N, Leray E, Fergelot P, et al. The Fuhrman grade: a European multicenter study for the determination of the optimal grading system in term of prognosis. Eur Urol suppl. 2006; 5: 67-70.
53. Mejean A, Oudard S, Thiounn N. Prognostic factors of renal cell carcinoma. J Urol. 2003;169(3):821-827.
54. Dall'Oglio M, Aap MA, Antunes AA, Cury J, Leite KR, Srougi M. Impact of clinicopathological parameters in patients treated for renal cell carcinoma. J Urol. 2007;177(5):1687-1691.
55. Patard JJ, Leray E, Rioux-Leclercq N, Cindolo L, Ficarra V, Zisman A, et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol. 2005; 23(12):2763-2771.
56. Lam JS, Shvarts O, Said JW, Pantuck AJ, Seligson DB, Aldridge ME, et al. Clinicopathologic and molecular correlations of necrosis in the primary tumor of the primary tumor patients with renal cell carcinoma. Cancer. 2005;103(12):2517-2525.
57. Martignoni G, Brunelli M, Gobbo S, Remo A, Ficarra V, Cossu-Rocca P, et al. Role of molecular markers in diagnosis and prognosis of renal cell carcinoma. Anal Quant Cytol Histol. 2007;29(1):41-49.
58. Bui MH, Seligson D, Han KR, Pantuck AJ, Dorey FJ, Huang Y, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res. 2003;9(2):802-811.
59. Jacobsen J, Grankvist K, Rasmuson T, Ljungberg B. Different isoform patterns for vascular endothelial growth factor between clear cell and papillary renal carcinoma. BJU Int. 2006;97(5):1102-1108.
60. Ljungberg BJ, Jacobsen J, Rudolfsson SH, Lindh G, Grankvist K, Rasmuson T. Diferent vascular endothelial growth factor (VEGF), VGF-receptor 1 and 2 mRNA expression profiles between clear cell and papillary renal cell carcinoma. BJU Int. 2006;98(3):661-667.
61. Yildiz E, Gokce G, Kilicarslan H, Ayan S, Goze OF, Gultekin EY. Prognostic value of the expression of Ki-67, CD44 and vascular endothelial growth factor, and microvessel invasion, in renal cell carcinoma. BJU Int. 2004;93(7):1087-1093.
62. Lam JS, Leppert JT, Yu H, et al. Expression of the vascular endothelial growth factor family in tumor dissemination and disease free survival in clear cell renal cell carcinoma. J Clin Oncol. 2005;23(Suppl):387s (abstract no. 4538).
63. Onda H, Yasuda M, Serizawa A, Osamura RY, Kawamura N, et al. Clinical outcome in localized renal cell carcinoma related to immunoexpression of proliferating cell nuclear antigen, Ki-67 antigen, and tumor size. Oncol Rep. 1999;6(5):1039-1043.
64. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol. 2002;168(6):2395-2400.
65. Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, et al. Prognostic factors for survival in previously treated patient with metastatic renal cell carcinoma. J Clin Oncol. 2004;22(3):454-463.
66. Cindolo L, de la Taille A, Messina G, Romis L, Abbou CC, Altieri V, et al. A prospective clinical prognostic model for non-metatatic renal cell carcinoma. BJU Inte. 2003;92(9):901-905.
67. Karakiewicz PI, Hutterer GC. Predicting cancer-control outomes in patients with renal cell carcinoma. Curr Opin Urol. 2007;17(5):295-302.
68. Ljungberg B, Hanbury DC, Kuczyk MA et al. Guidelines on Renal Cell Carcinoma 2007. www.uroweb.org.